GlassScriptPhysician profile
Anil Kumar Saxena
NPI 1841297504
$1,803.75
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $81.16 · 2021: $492 · 2022: $547 · 2023: $70.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $363.12 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.24 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $334.23 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $330.10 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $109.35 | 2019-2020 | |
| Novo Nordisk INC | $91.35 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $62.46 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $45.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.70 | 2019 | |
| Amarin Pharma, INC. | $23.12 | 2022 | |
| Medtronic, INC. | $20.40 | 2021 | |
| Tandem Diabetes Care, INC. | $19.28 | 2019 | |
| Lilly USA, LLC | $17.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Saxena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.